AIM ImmunoTech Inc. Common Stock AIM 深 滬
等待開盤 03-26 09:30:00 美东时间
0.8526
-0.118
-12.15%
華盛通- 最 高0.9916
- 今 開0.9916
- 成交量 101.95万股
- 最 低 0.8401
- 昨 收 0.9705
- 總市值 359.84万
- 52周最高 20.3297
- 市盈率 靜 --
- 換手率 24.16%
- 52周最低 0.6141
- 委 比 0.00%
- 總股本 422.05万
- 歷史最高 20.3297
- 量 比 0.03
- 振 幅 15.61%
- 歷史最低 0.6141
- 每 手 1
- 風險率 2.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scheduled For March 24, 2026
Companies Reporting Before The Bell • Fennec Pharmaceuticals (NASDAQ:FENC) is e...
03-24 19:11
What's Going On With AIM ImmunoTech Stock Friday?
AIM ImmunoTech (AMEX: AIM) sees bullish momentum after final patent approval in Japan for its Ampligen-based oncology treatments.
03-20 23:07
Why Is AIM ImmunoTech Stock Gaining Today?
AIM ImmunoTech stock surges after Japan fully approved a patent covering Ampligen with checkpoint inhibitors, strengthening its cancer-treatment IP portfolio.
03-19 00:08
AIM ImmunoTech Secures Full Japanese Patent For Ampligen Use With Checkpoint Inhibitors In Cancer Treatment
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company's proprietary use of Ampligen (rintatolimod) in
03-18 20:38
AIM ImmunoTech wins final Japan patent approval for Ampligen-checkpoint inhibitor cancer therapy
AIM ImmunoTech wins final Japan patent approval for Ampligen-checkpoint inhibitor cancer therapy AIM ImmunoTech said the Japan Patent Office fully approved a Japanese patent covering the use of Ampligen in combination with checkpoint inhibitors for treating cancer. The company said the patent includ
03-18 20:36
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
AIM ImmunoTech Inc. announced the full approval of a Japanese patent covering the use of Ampligen (rintatolimod) in combination with checkpoint inhibitors for cancer treatment, including pancreatic cancer. The patent, granted in September 2025, expires December 20, 2039. AIM also plans to pursue orphan drug designation in Japan for Ampligen in the treatment of pancreatic cancer, joining existing designations in the U.S. and EU. The company aims t...
03-18 12:36
AIM ImmunoTech Inks Deal With Thermo Fisher Scientific's PPD Clinical Research Business To Design AIM's Phase 3 Study In Use Of Ampligen Drug
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM's anticipated Phase 3 clinical trial in
03-02 22:06
BRIEF-AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic Cancer
BRIEF-AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic Cancer March 2 (Reuters) - AIM ImmunoTech Inc AIM.A : AIM IMMUNOTECH SIGNS AGREEMENT FOR PLANNING OF A PROPOSED PHASE 3 CLINICAL TRIAL OF AMPLIGEN IN THE TREAT
03-02 22:01
AIM ImmunoTech Partners With Thermo Fisher’s PPD to Plan Ampligen Phase 3 Pancreatic Cancer Trial
AIM ImmunoTech Partners With Thermo Fisher’s PPD to Plan Ampligen Phase 3 Pancreatic Cancer Trial AIM ImmunoTech Inc. has signed an agreement with the PPD clinical research business of Thermo Fisher Scientific to design a proposed Phase 3 clinical trial of Ampligen for late-stage pancreatic cancer.
03-02 22:01
